[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536002":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":30,"responsibleParty":44,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":11,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LAG-3 expression\u002Fimmune checkpoint protein expression evaluation","EXPERIMENTAL",null,[13],"Procedure: LAG-3 expression \u002F immune checkpoint protein expression",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","LAG-3 expression \u002F immune checkpoint protein expression","Evaluate the tissue and blood before and after chemotherapy",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Ji-Yeon Kim","CONTACT","82-2-3410-3459","jyeon25@skku.edu",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},"Mee Ryung Hong","82-2-2148-7147","ring7629@naver.com",[31],{"facility":22,"status":32,"city":33,"state":11,"zip":34,"country":35,"countryCode":11,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Seoul","06351","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},[43],{"name":22,"role":23,"phone":11,"phoneExt":11,"email":11},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","JI-YEON, KIM","Professor","100536002","lag3-expression-in-triple-negative-breast-cancer-100536002",false,"NCT06259162","LAG3 Expression in Triple Negative Breast Cancer","The Evaluation the Relationship Between LAG-3 Expression \u002F Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer","Inclusion Criteria:\n\n* Planned neoadjuvant chemotherapy\n* Triple negative breast cancer\n\nExclusion Criteria:\n\n* HER2-positive breast cancer\n* Hormone receptor positive breast cancer",true,"FEMALE",{"count":58,"type":59},128,"ESTIMATED","INTERVENTIONAL",[62],"NA","This study is the experimental study for relationship between LAG-3 expression \u002F immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.",[65,66],"Triple Negative Breast Cancer","Immune Checkpoint Inhibitor","2024-02-06",{"date":69,"type":70},"2024-02-14","ACTUAL",{"date":72,"type":70},"2022-11-18",{"date":74,"type":59},"2027-12-31",{"name":5,"class":6},1]